TITLE

Combination therapy more effectively induces remission of major depressive disorder

PUB. DATE
June 2010
SOURCE
JAAPA: Journal of the American Academy of Physician Assistants (;Jun2010, Vol. 23 Issue 6, p53
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study which found that combination therapy with mirtazapine and other antidepressant medications is more effective than just fluoxetine for achieving remission of major depression.
ACCESSION #
52159578

 

Related Articles

  • A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. Young, J.P.R; Hughes, W.C.; Lader, M.H. // British Medical Journal;5/8/1976, Vol. 1 Issue 6018, p1116 

    Investigates the amitriptyline or flupenthixol treatment on depressed patients under double-blind procedures. Consideration on the treatment procedures; Developments on patients after treatments; Absence of distinct characteristics of drug effectivity.

  • Pharmacological means to improve patients' mood. Are they effective and safe? Zylicz, Zbigniew Ben // Medycyna Paliatywna w Praktyce;2016, Vol. 10 Issue 4, p155 

    Low mood and depression can be treated with many non-pharmacological means. However, in terminally ill these means are sometimes insufficient and the doctors need to prescribe drugs. In this article I shall discuss simple and proven drugs that improve patients mood and, some of them do have...

  • Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. Zhang Xiaoling; Han Yunping; Lian Yingdong // Pakistan Journal of Pharmaceutical Sciences;2018 Special Issue, Vol. 31, p1115 

    Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life. This study compared efficacy of escitalopram and fluoxetine on depression patients, and analyzed the inflammatory factors, serum homocysteine (Hcy)...

  • Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. Kasper, Siegfried; Anghelescu, Ion-George; Szegedi, Armin; Dienel, Angelika; Kieser, Meinhard // BMC Medicine;2006, Vol. 4, p1 

    Background: The aim of the current study was to assess the antidepressant efficacy and safety of Hypericum perforatum (St. John's wort) extract WS® 5570 at doses of 600 mg/day in a single dose and 1200 mg/day in two doses. Methods: The participants in this double-blind, randomized,...

  • The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. Mallinckrodt, Craig H.; Raskin, Joel; Wohlreich, Madelaine M.; Watkin, John G.; Detke, Michael J. // BMC Psychiatry;2004, Vol. 4, p26 

    Background: A mixed-effects model repeated measures approach (MMRM) was specified as the primary analysis in the Phase III clinical trials of duloxetine for the treatment of major depressive disorder (MDD). Analysis of covariance using the last observation carried forward approach to impute...

  • Doubt cast on NICE advice over tricyclics and SSRIs. Gough, Rob; Kelly, Bran // Pulse;9/29/2003, Vol. 63 Issue 39, p2 

    Presents a study negating the recommendation made by Great Britain National Institute for Clinical Excellence against the prescription of tricyclics by general practitioners. Preference for the prescription of selective serotonin reuptake inhibitors in treating depression; Suggestion of equal...

  • Cannabis as a substitute for prescription drugs - a cross-sectional study. Corroon, James M.; Mischley, Laurie K.; Sexton, Michelle // Journal of Pain Research;May2017, Vol. 10, p989 

    Background: The use of medical cannabis is increasing, most commonly for pain, anxiety and depression. Emerging data suggest that use and abuse of prescription drugs may be decreasing in states where medical cannabis is legal. The aim of this study was to survey cannabis users to determine...

  • Venlafaxine and paroxetine in treatment-resistant depression. Poirier, M.-F.; Boyer, P. // British Journal of Psychiatry;Jul99, Vol. 175, p12 

    Background About one-third of patients fail to respond to initial antidepressant therapy, which suggests a need for more effective drugs. Aims To compare the efficacy and safety of venlafaxine and paroxetine in 122 patients with non-chronic treatment-resistant depression. Method In-patients or...

  • A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State. Patkar, Ashwin; Gilmer, William; Chi-un Pae; Vöhringer, Paul A.; Ziffra, Michael; Pirok, Edward; Mulligan, Molly; Filkowski, Megan M.; Whitham, Elizabeth A.; Holtzman, Niki S.; Thommi, Sairah B.; Logvinenko, Tanya; Loebel, Antony; Masand, Prakash; Nassir Ghaemi, S. // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Objective: To examine the efficacy of ziprasidone vs. placebo for the depressive mixed state in patients with bipolar disorder type II or major depressive disorder (MDD). Methods: 73 patients were randomized in a double-blinded, placebo-controlled study to ziprasidone (40-160 mg/d) or placebo...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics